Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: Most allografts with proteinuria >1500 mg/dL have new glomerular pathology. In contrast, lower levels of proteinuria are generally associated with non-glomerular, nonspecific histologic changes. The relationship between proteinuria and graft survival is independent of other variables1, allowing stratification of risk in patients with or without glomerular pathology. Donor-derived cell-free DNA (dd-cfDNA) is also known to allow risk stratification of patients, quantifying molecular injury. As proteinuria is routinely monitored periodically post-transplant, once present it suggests the damage has already occurred. Assessing whether elevation in dd-cfDNA is predictive of new proteinuria may help to predict long term outcome.
*Methods: 99 patients identified from the DART study had dd-cfDNA (AlloSure®) and proteinuria measured 1-10 times during the first-year post transplant and 1-6 times during follow up visits during the second year. Clinically significant proteinuria was defined as patients with grade ‘++’ proteinuria or higher on urine dipstick sustained over 3 visits. The fraction of patients with positive proteinuria from year two was compared to the fraction from year one (day 14-365) in patients with ≥1 elevated dd-cfDNA (AlloSure ≥1%) in the first year vs. those without dd-cfDNA elevation. Association between elevated dd-cfDNA (≥1%) in year 1 and de novo positive proteinuria in year 2 was also tested.
*Results: 20 patients with ≥ 1 elevated dd-cfDNA in days 14 – 365 were compared to 79 patients without dd-cfDNA elevation. Proteinuria was more common in the second year in patients with elevated dd-cfDNA in the first year (4/20 = 20%) than in those without (0/79 = 0%, P = 0.001, Fisher’s exact test). Of the 82 patients who did not have positive proteinuria in the first year, patients with elevated dd-cfDNA in year 1 were more likely to develop de novo proteinuria in year 2 (8%) than those without elevated dd-cfDNA (0%), however due to the small sample size this was not statistically significant (p=0.146, Fisher’s exact test).
*Conclusions: The cause of new or worsening proteinuria remains multifactorial; however, elevations in 1st year AlloSure® dd-cfDNA (≥1%) are associated with significant increase in proteinuria in year 2. dd-cfDNA as a marker of injury may have utility beyond detecting acute events, where regular surveillance may be a useful tool in prediction of long-term outcomes, especially when combined with other measures of immune injury to allografts.
To cite this abstract in AMA style:Jordan S, Sood P, Bromberg J, Brennan D. The Use of dd-cfDNA as a Predictive Tool for Future Proteinuria [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-use-of-dd-cfdna-as-a-predictive-tool-for-future-proteinuria/. Accessed December 6, 2023.
« Back to 2020 American Transplant Congress